Form 8-K · Current report
Johnson & Johnson 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000200406
- Accession no.
- 0000200406-26-000167
Summary
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine effective September 1, 2026, and that Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her and join the Executive Committee on the same date.
Key points
- Taubert spent over 21 years at Johnson & Johnson, during which the Innovative Medicine business grew to more than $60 billion in annual revenue.
- Cavanaugh joined Johnson & Johnson in 2017 and previously spent nearly 15 years at Celgene in product development, medical affairs, and marketing roles.
- Chairman and CEO Joaquin Duato said Cavanaugh's knowledge of the business and record of growth position the company to continue delivering for patients and healthcare systems.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
- 9.01Financial Statements and Exhibits
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026. The Company’s related press release is attached to this Report as Exhibit 99.1. Item 9.01 Financial statements and exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated August 4, 2026. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.